Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gelesis Presents Data Showing GS200, The Device That Looks Like A Drug, Treats Obesity

Executive Summary

Results of the LIGHT UP study, which included prediabetic and diabetic subjects, could support FDA approval of GS200.

You may also be interested in...



BaroNova’s TransPyloric Shuttle Earns FDA-Approval To Treat Obesity

Patients treated with the TransPyloric Shuttle in the 213-patient ENDObesity II trial lost an average of 9.5% of their body-weight and 30.9% of their excess weight.

Results Recap: Trial Results Presented At ObesityWeek, AHA, And Veith Meetings

Results Recap is Medtech Insight's exclusive summary of clinical trial results that have been announced or published in the past week, based on information collected by Meddevicetracker. This week's edition, covering the week of Nov. 9 - Nov. 15, includes trial data presented at the Veith symposium Nov. 13 - 17 in New York, the American Heart Association Scientific Sessions in Chicago Nov. 10 - 12, and the ObesityWeek meeting in Nashville Nov. 11 - 15.

Novo Nordisk, Embark Seek Obesity Drugs That Boost Body's Energy Use

Danish duo enter pact to discover novel therapeutics for obesity and related metabolic diseases using mechanisms that increase the body's expenditure of energy.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT145363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel